Axel Finckh, EULAR 2022: Findings from the “JAK-pot” Study
The “JAK-pot” study compared the safety of JAK inhibitors (JAKis) to other biologic agents in the treatment of patients with rheumatoid arthritis (RA). touchIMMUNOLOGY were delighted to speak with Prof. Axel Finckh (University of Geneva, Geneva, Switzerland) to discuss real world safety and tolerability of JAKis and treatment discontinuation for JAKis compared to other treatments for RA in the JAK-pot study.
The abstract ‘Treatment discontinuation due to adverse events as an overall measure of tolerance and safety of JAK-inhibitors: An international collaboration of registries of rheumatoid arthritis patients (the “JAK-pot” study).‘ (Abstract number: OP0266) was presented at the European Congress of Rheumatology 2022, 1-4 June, 2022.
Questions
- What has been the impact of JAK inhibitors on the treatment paradigm for rheumatoid arthritis? (0:15)
- What is known about the tolerability and safety of JAK inhibitors in real world use? (1:20)
- How did treatment discontinuation for JAK inhibitors compare to those of other treatments, and what factors affected treatment discontinuation? (2:32)
- What were the conclusions of the investigators, and what further research is required? (4:02)
Disclosures: Axel Finckh discloses receiving grant/ research support from AbbVie, BMS, Galapagos, Eli-Lilly and Pfizer; and honoraria from Astra-Zeneca, AbbVie, BMS, Eli-Lilly and Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EULAR meeting 2022.
